MDR1 Causes Resistance to the Antitumour Drug Miltefosine

British Journal of Cancer - United Kingdom
doi 10.1054/bjoc.2001.1776
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Anti-Leishmanial Drug Miltefosine Causes Insulin Resistance in Skeletal Muscle Cells in Vitro

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2006English

P53-Dependent Regulation of MDR1 Gene Expression Causes Selective Resistance to Chemotherapeutic Agents

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1997English

Chemical and Bioassay Techniques to Authenticate Quality of the Anti-Leishmanial Drug Miltefosine

American Journal of Tropical Medicine and Hygiene
MedicineVirologyParasitologyInfectious Diseases
2015English

Resistance and Cross-Resistance of Escherichia Coli Mutants to Antitumour Agent Mitomycin C

Journal of General Microbiology
1961English

Low Plasma Membrane Expression of the Miltefosine Transport Complex Renders Leishmania Braziliensis Refractory to the Drug

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2009English

Multidrug-Resistance P-Glycoprotein (MDR1) Secretes Platelet-Activating Factor

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2001English

Antitumour Antibiotics

British Journal of Cancer
Cancer ResearchOncology
1979English

Carfilzomib Resistance Due to ABCB1/MDR1 Overexpression Is Overcome by Nelfinavir and Lopinavir in Multiple Myeloma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2017English

ATP7A and Drug Resistance and Clinical Drug Resistance

Cancer Research
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy